WO2006041158A1 - 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 - Google Patents
雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 Download PDFInfo
- Publication number
- WO2006041158A1 WO2006041158A1 PCT/JP2005/018957 JP2005018957W WO2006041158A1 WO 2006041158 A1 WO2006041158 A1 WO 2006041158A1 JP 2005018957 W JP2005018957 W JP 2005018957W WO 2006041158 A1 WO2006041158 A1 WO 2006041158A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gaba
- spray
- spraying
- solution
- propellant
- Prior art date
Links
- 239000007921 spray Substances 0.000 title claims description 78
- 238000000034 method Methods 0.000 title claims description 16
- 239000007788 liquid Substances 0.000 title description 15
- 239000002904 solvent Substances 0.000 claims abstract description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 92
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 79
- 238000005507 spraying Methods 0.000 claims description 43
- 239000003380 propellant Substances 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 27
- 239000012298 atmosphere Substances 0.000 claims description 24
- 238000002715 modification method Methods 0.000 claims description 16
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 4
- AJYLWDRNNNHBEV-UHFFFAOYSA-N 2-hydrazinylbutanoic acid Chemical compound CCC(NN)C(O)=O AJYLWDRNNNHBEV-UHFFFAOYSA-N 0.000 claims 1
- 229940124277 aminobutyric acid Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 29
- 230000009471 action Effects 0.000 description 12
- 238000007590 electrostatic spraying Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 239000006199 nebulizer Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035985 Body Odor Diseases 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040904 Skin odour abnormal Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 229930182559 Natural dye Natural products 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- Atmospheric modification method and propellant and spray device used therefor
- the present invention relates to a method for modifying an atmosphere of a body space or an indoor space, and a propellant and a spray device used therefor.
- GABA ⁇ -aminobutyric acid
- Its pharmacological action is, for example, blood pressure regulation action that normalizes blood pressure, action that suppresses the increase of cholesterol and triglyceride in blood, action that activates the action of kidney, liver and spleen, and suppresses increase in blood glucose level Effects, activation of brain cell metabolism by improving the blood flow to the brain, anti-obesity effect, alcohol metabolism promoting effect, deodorizing effect such as body odor and bad breath, relieving emotional disorder and anxiety disorder It has the effect of improving the sequelae of stroke, the action of suppressing colon cancer, and the action of promoting growth hormone secretion. For this reason, GAB A has attracted much attention in recent years as a supplement.
- Patent Document 1 discloses that by taking GABA orally, it directly increases the appearance of brain alpha waves and decreases the appearance of beta waves.
- Patent Document 2 discloses a GABA-containing food / beverage product inoculating and culturing a food material containing a protein or peptide containing glutamic acid as a constituent amino acid with a microorganism capable of producing protease and a microorganism capable of producing glutamate decarboxylase. The manufacturing method is disclosed. And, according to this, it is described that GABA-containing foods and drinks with good taste and color tone can be obtained efficiently by adding glutamic acid as a food additive.
- GABA is taken orally, it cannot pass through the cerebrovascular barrier and cannot reach the brain, and it is metabolized when it passes through the liver after being absorbed in the small intestine. There is. Therefore, GABA analogs that do not have such problems as GABA itself are used.
- Patent Document 3 discloses a pharmaceutical composition comprising an effective amount of a GABA analog. The According to this, it is described that insomnia in mammals can be treated.
- Patent Documents 4 and 5 disclose that a GABA analog is administered orally or parenterally such as nasal administration. However, there is no mention of any specific means for nasal administration.
- An object of the present application is to provide an atmosphere modification method in which GABA can be taken into the body by a completely different method, and a propellant and a spray device used therefor.
- Patent Document 1 Japanese Patent Laid-Open No. 2003-252755
- Patent Document 2 Japanese Patent Laid-Open No. 2000-14356
- Patent Document 3 Japanese Translation of Special Publication 2002-520277
- Patent Document 4 Japanese Patent Laid-Open No. 2001-131161
- Patent Document 5 JP 2001-342150 A
- the atmosphere modifying method of the present invention is characterized in that a solution in which GABA is dissolved as a solute in a solvent is sprayed into the space.
- GABA solution is sprayed into the space, GABA is absorbed into the nasal mucosa and pulmonary, so that GABA can be taken into the body without pilling. .
- GABA is absorbed by the nasal mucosa in the sinuses and enters not only blood vessels but also lymph, and GABA entering lymph does not cross the cerebrovascular barrier! Therefore, it is not an analog! GABA It can be taken into the brain.
- GABA is absorbed through the nasal mucosa and through the lung and does not pass through the portal vein, metabolism due to the first passage of the liver can be avoided.
- the solution is preferably sprayed to a particle size of 10 ⁇ m or less. More preferably, spraying is performed at 5 / zm or less.
- the particle diameter of the solution is sufficiently small! /, So that it is easy to enter the nose and lungs, and the absorption is smoothly performed.
- the particle size of the solution is larger than 10 m, many will enter the stomach via the throat without entering the nose or lungs.
- the particle size is such that particles released into the space do not settle in a short time. If the particle size is 10 ⁇ m, it settles 60 cm per minute, and the sedimentation distance is proportional to the square of the particle size, so if the particle size is 1 ⁇ m, it is 0.6 cm per minute and the particle size is 5 ⁇ m. For example, it settles 15-20 cm per minute. Considering the presence of convection, the particle size is more preferably 5 ⁇ m or less.
- the particle size of the solution is an average particle size.
- the concentration of 088 in the space is 10 / ⁇ 111 3 to 100111 8 / m 3 .
- spraying of the solution in which GABA is dissolved may be controlled such that the spray amount per unit time is larger at the start of spraying than during steady spraying.
- the concentration of GABA in the space can be increased in a short time from the start of spraying.
- spraying of the solution in which the GABA is dissolved may be controlled so that the concentration of GABA in the space becomes constant.
- GABA can be stably and continuously taken into the body.
- the spraying of the solution in which GABA is dissolved may be controlled to start after a lapse of a certain period of time from detection of falling asleep.
- the GABA intake efficiency becomes the highest after a certain period of sleep onset ability, so that growth hormone secretion can be effectively promoted.
- the propellant of the present invention used for the atmosphere modification method of the present invention is sprayed into a space.
- GABA is dissolved as a solute in a solvent.
- the spray of the present invention may have a GABA concentration of 0.0017-3. 88 molZl.
- an appropriate amount of GABA can be taken into the body, and the liquid property of the propellant is appropriate.
- the usage mode is such that the spray amount per unit time is increased and the propellant is replenished in a short cycle (for example, 1 day), and the spray amount per unit time is decreased to a longer cycle (for example, 2 to 2). It is possible to cope with deviations in usage patterns such as replenishing the propellant in 3 months.
- the GABA concentration is as low as 0.0017 molZU, it is necessary to increase the particle size and spray amount to obtain the effect, and the concentration is not stable in the air due to the effect of sedimentation, etc. If the particle size is reduced to suppress sedimentation, the intake into the body is reduced and the effect is diminished.
- the spray of the present invention preferably has a GABA concentration of 1.94 molZl or less. This is particularly suitable in the case of a usage form in which the amount of spray per unit time is increased and the propellant is replenished in a cycle.
- the GABA concentration of 0.0017 to 3.88 molZl corresponds to 0.1 to 40% by mass when the solvent is water.
- the spray of the present invention can be sprayed into a space by a spraying device such as a nebulizer.
- FIG. 1 is a graph showing the relationship between the particle size of a solution sprayed by an ultrasonic nebulizer and its ratio.
- FIG. 2 is a graph showing the relationship between the particle size of a solution and its ratio when sprayed with an ink jet spray device.
- FIG. 3 is a graph showing the relationship between the particle size of a solution and its proportion when sprayed by an electrostatic atomizing spray device.
- ⁇ 4 It is a schematic block diagram of an electrostatic spraying device (10).
- FIG. 5 is a perspective view of a spray cartridge (15).
- FIG. 6 is a cross-sectional view showing a main part of the spray cartridge (15).
- FIG. 7 (A) is a cross-sectional view illustrating the tip of the spray nozzle (31) during spraying, and (B) is a cross-sectional view illustrating the tip of the spray nozzle (31) while spraying is stopped.
- the space atmosphere modification method of the present embodiment is such that a spray containing GABA is sprayed into the air with a spray device, and GABA is taken into the human body by nasal mucosal absorption or pulmonary absorption. I will try to let you.
- This propellant is basically a solution in which GABA is dissolved as a solute in a solvent.
- the propellant is also blended with conductivity adjusters, solubilizers, suspending agents, tonicity agents, buffers, soothing agents, etc.
- Formulation additives such as antioxidants, colorants, sweeteners, and fragrances are blended.
- GABA is represented by the following formula.
- GABA is an inhibitory neurotransmitter present in high concentrations in the central nervous system of mammals, but can also be synthesized artificially.
- GABA also has, for example, a blood pressure regulating action that normalizes blood pressure, an action that suppresses the increase of cholesterol and neutral fat in the blood, an action that activates the action of the kidneys, liver, and spleen, and an increase in blood sugar level.
- Suppressing action improving blood flow to the brain and activating brain cell metabolism, preventing obesity, promoting alcohol metabolism, deodorizing action such as body odor and bad breath, emotional disorder and anxiety disorder It has pharmacological effects such as relieving effect, improving stroke sequelae, inhibiting colon cancer, and promoting growth hormone secretion.
- solvent examples include water (including water for injection, physiological saline and Ringer's solution), alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, and cottonseed oil.
- Examples of the conductivity adjusting agent include ethanol and isopropanol.
- Solubilizing agents include, for example, polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, isopropanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, salicy. Sodium sulfate, sodium acetate and the like.
- Suspending agents include, for example, stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, surfactants (eg glyceryl monostearate), hydrophilic Polymers (e.g., polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethinoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresenorelose, etc.), polysorbates, polyoxyethylene hydrogenated castor oil, etc. It is.
- surfactants eg glyceryl monostearate
- hydrophilic Polymers e.g., polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethinoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresen
- Examples of the tonicity agent include sodium chloride salt, glycerin, D-mannitol, D-sorbitol, glucose and the like.
- the buffering agent is, for example, a buffer solution of phosphate, acetate, carbonate, citrate, or the like.
- the soothing agent is, for example, benzyl alcohol.
- Examples of the preservative include paraoxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, and the like.
- antioxidants examples include sulfite and ascorbate.
- Coloring agents include, for example, water-soluble colored tar dyes that are food dyes such as food red No. 2 or 3, food yellow No. 4 or 5, food blue No. 1 or No. 2, and the like.
- Insoluble lake dyes such as aluminum salts of edible tar dyes, 13 natural dyes such as roten, chlorophyll, and bengara.
- sweetening agent examples include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia and the like.
- the fragrance is, for example, a water-soluble essence for scent of lemon, lavender or cypress.
- the concentration of GABA in this propellant is preferably 0.0001-3.88 mol / U, more preferably 0.0001 to 1.94 molZl. If the concentration of GABA is within this range, an appropriate amount of GABA can be taken into the body, and the viscosity and liquid properties of the soluble propellant will be appropriate.
- a GABA concentration of 0.0017-1.94 molZl is suitable for use forms in which the amount of spray per unit time is increased and the propellant is replenished in a short cycle.
- the propellant and the GABA dissolved in water as a solvent ne th to those in the concentration 0. 0097 ⁇ 3.
- the concentration of GABA 0. 0097 ⁇ 1.94 mol Zl corresponds to 0.1 to 20% by mass.
- the propellant preferably has a conductivity of 50 to: L000 ⁇ s / cm, more preferably 100 to 300 ⁇ s Zcm. If the electrical conductivity is within this range, the spray state is stable and large particles are not generated, so particles do not adhere to the tip of the circular spray nozzle, which is one of the causes of clogging. In order to reduce the conductivity, it is necessary to increase the ratio of petroleum added.
- the upper limit is set by the Fire Service Law, and the above range is more preferable to comply with this.
- the propellant preferably has a viscosity of 0.1 to 5. lcP, more preferably 0.1 to 3.0 cP.
- lcP a viscosity of 0.1 to 5.
- 0.1 to 3.0 cP troubles such as clogging of the spraying device are unlikely to occur.
- This figure shows that when spraying with a tubular spray nozzle of 0.4 to 0.6 mm, it is possible to spray by increasing the applied voltage or increasing the conductivity even if the viscosity is high. It is not preferable because it is necessary to increase the solution ratio.
- the spraying device is, for example, a nebulizer for inhaling a chemical solution that sprays the above-mentioned spray into the human body space, or a sprayer provided in an air conditioner that sprays the above-mentioned spray into the indoor space.
- a spraying method of the spraying device include an ultrasonic method, a bubble jet method, a piezo method, and an electrostatic atomization method.
- the solution having a sufficiently small particle diameter is easier to enter the nose and lungs, and the absorption is performed smoothly.
- the diameter is preferably 10 ⁇ m or less, more preferably 5 ⁇ m or less.
- the intake of an appropriate amount of GA BA in the body it is preferable to the concentration of GABA in the space 10 gZm 3 ⁇ 100m gZm 3 by spraying.
- the maximum intake of GABA into the body is about lOOOmg per day.
- GABA is absorbed through the nasal mucosa and pulmonary, so there is no need to remove tablets
- ABA can be taken into the body.
- GABA is absorbed in the nasal mucosa in the sinuses and enters not only blood vessels but also lymph, and GABA entering lymph does not cross the cerebrovascular barrier! Therefore, it is not an analog! GABA It can be taken into the brain.
- GABA is absorbed through the nasal mucosa and through the lung and does not pass through the portal vein, metabolism due to the first passage of the liver can be avoided.
- the GABA concentration in the blood can be maintained at a high level for a long time, thereby promoting the secretion of growth hormone. I'll do it.
- FIG 4 to 6 show an electrostatic spraying device (10) according to an embodiment of the present invention.
- the electrostatic spraying device (10) includes a spray cartridge (15), a power source (16), and a control unit (17).
- the spray cartridge (15) includes a solution tank (20), a nose, a nose unit (30), an electrode holder (40), and a ring electrode (35).
- the solution tank (20) includes a hollow tank body (21) having an air vent hole (25) formed in the top plate. Near the lower end of the front surface of the tank body (21), a pipe portion (23) protruding in the horizontal direction is provided. The pipe part (23) communicates with the tank body (21) through a through hole (24) formed in the front wall of the tank body (21).
- the nozzle unit (30) includes a circular spray nozzle (31) having an inner diameter of, for example, 0.4 to 0.6 mm, and a cylindrical bottomed cap-shaped nozzle holder (32).
- the nozzle holder (32) is provided so as to cover the pipe portion (23).
- the spray nozzle (31) has its base end inserted into the center of the bottom of the nozzle holder (32), thereby leading to the tank body (21) via the pipe (23) and the through hole (24). Yes.
- the nozzle holder (32) is provided with a terminal portion (33) formed so as to extend from the outer periphery to the side. Nozzle holder (32) and terminals
- the part (33) is composed of an electrode made of conductive grease, and the spray nozzle (31) is electrically connected thereto.
- the electrode holder (40) is concentrically provided with an interval between the inner cylinder portions that are concentrically coupled to each other on the proximal end side.
- the electrode holder (40) is provided so that the inner cylinder (41) fits into the nozzle holder (32)! /
- the electrode holder (40) has a ring electrode formed in an annular shape with a terminal portion (36) formed of a tongue protruding laterally on the outer peripheral edge on the distal end side of the outer tube portion (42). It is fitted.
- the power supply (16) is a DC high-voltage power supply. This power source (16) is connected to the spray nozzle (31) via the terminal part (33) of the positive terminal force squel holder (32), and the grounded negative terminal is connected to the terminal part of the ring electrode (35). (36) are electrically connected to each other.
- the control unit (17) is configured to perform on / off switching control of the power source (16).
- the heat insulating material is provided to the tank main body (21).
- a heat insulating mechanism such as providing a heater may be configured, or a heating mechanism such as a surface heater may be attached.
- a spray containing GABA is stored in the tank body (21) of the solution tank (20).
- the propellant preferably has a GABA concentration of 0.0017 to 3.8 8 molZl, more preferably 0.009 to 94 molZl, and a viscosity of preferably 0.1 to 5. lcP, more preferably 0. 1-3. OcP.
- the conductivity is preferably 50 to 1000 57 «11, more preferably 100 to 300 / z sZcm.
- the position of the liquid level (51) in the tank body (21) is between the liquid level (51) in the tank body (21), which is higher than the tip of the spray nozzle (31), and the tip of the spray nozzle (31). Since there is a difference in the head, the spray in the tank body (21) is supplied to the tip of the spray nozzle (31).
- the occupant inhales the propellant droplets with the air as they breathe.
- the droplet size is preferably as small as 10 m or less, more preferably 5 ⁇ m or less.
- the spray nozzle (31) and the ring electrode (35) have the same potential, and the gas-liquid interface (52) formed at the tip of the spray nozzle (31) As shown in FIG. 7 (B), since the surface tension and the hydraulic pressure due to the head difference are balanced, the aqueous solution does not flow out from the tip of the spray nozzle (31). Specifically, even when a liquid pressure of, for example, 20 mmH 2 O acts on the gas-liquid interface (52) at the tip of the spray nozzle (31), the aqueous solution (50
- control unit (17) is configured to turn on the power supply (16) (on time) and turn off the power supply (16) (off time).
- the operation of spraying the propellant is controlled by controlling the duty ratio.
- the duty ratio is set higher at the start of spraying than at the time of steady spraying. It is controlled so that the spray amount per unit time becomes higher. As a result, the concentration of GABA in the space can be increased in a short time with the spray start force.
- the pressure applied to the propellant loaded by the spray nozzle (31) depends on the height of the liquid surface (51) in the solution tank (20).
- the duty ratio is set according to the height of the liquid level (51) (the higher the liquid level (51), the lower the duty ratio), so that the GABA concentration in the space becomes constant. Controlled. Thereby, the intake of GABA into the body can be performed stably and continuously.
- the spraying of the solvent from the propellant if the spraying of the solvent from the propellant, selective electric field attraction of the solvent, or formation of a concentration gradient due to the difference in momentum between GABA and the solvent occurs, the viscosity of the propellant An ascent may occur, which may cause clogging of the spray nozzle (31).
- the power is supplied for a predetermined time (for example, 5 to 20 seconds) at regular intervals (for example, every 1 to 10 minutes) during spraying or stopping of the propellant. Control is made to repeat the formation and extinction of the electric field by repeating ON and OFF of (16) (for example, repetition frequency of 0.1 to: LO. 0 Hz).
- the spray agent When the power supply (16) is turned on and an electric field is formed, the spray agent gradually swells at the tip of the spray nozzle (31), while when the power supply (16) is turned off and the electric field disappears.
- the propellant swelled due to the tip force of the spray nozzle (31) is retracted into the spray nozzle (31).
- the propellant repeats the behavior of exiting and retracting against the spray nozzle (31), and is agitated by this movement. As a result, it is possible to suppress an increase in the concentration of the propellant at the tip of the spray nozzle (31).
- a sleep onset detection sensor (not shown) connected to the control unit (17) detects sleep on the person, Control is performed so that spraying of the propellant is started after a certain period of time has elapsed since detection (for example, after 1 hour). Since GABA A intake efficiency is highest after a certain period of sleepiness, it can effectively promote growth hormone secretion.
- an optimal spray amount may be set by inputting the gender and Z or weight and Z or age of the sleeper.
- a spray of a 10% by weight aqueous solution of GABA was sprayed with an ultrasonic nebulizer, an inkjet sprayer, and an electrostatic atomizer sprayer, and the particle size distribution of the solution at that time was measured by QCM. Measurements were made using a cascade impactor and DMA (differential mobility analyzer). The measurement was carried out at a location 2 to 3 cm from the spray nozzle.
- FIG. 1 shows an ultrasonic nebulizer
- FIG. 2 shows an ink jet type spraying device
- FIG. 3 shows a relationship between the particle size of a solution and its ratio by spraying with an electrostatic atomizing type spraying device.
- Figures 1 and 2 show the measurement results with the QCM cascade impactor
- Figure 3 shows the measurement results with DMA.
- the particle size of the solution is almost 25 m, which is relatively large, whereas the spraying by the electrostatic atomization method is used.
- the present invention is useful for a method for modifying an atmosphere in a body space, an indoor space, and the like, as well as a propellant and a spray device used therefor.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05793078A EP1806133A1 (en) | 2004-10-14 | 2005-10-14 | Method for modifying the ambience, and spray liquid and sprayer used in the method |
US11/665,223 US20080112893A1 (en) | 2004-10-14 | 2005-10-14 | Atmosphere Modifying Method and Spray Agent and Spray Device Used in the Same |
AU2005292853A AU2005292853C1 (en) | 2004-10-14 | 2005-10-14 | Atmosphere modifying method and spray agent and spray device used in the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-299687 | 2004-10-14 | ||
JP2004299687 | 2004-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006041158A1 true WO2006041158A1 (ja) | 2006-04-20 |
Family
ID=36148444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018957 WO2006041158A1 (ja) | 2004-10-14 | 2005-10-14 | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080112893A1 (ja) |
EP (1) | EP1806133A1 (ja) |
KR (1) | KR100870381B1 (ja) |
CN (1) | CN101039664A (ja) |
AU (1) | AU2005292853C1 (ja) |
WO (1) | WO2006041158A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US20110232312A1 (en) | 2010-03-24 | 2011-09-29 | Whirlpool Corporation | Flexible wick as water delivery system |
CN112981713B (zh) * | 2021-02-09 | 2023-04-18 | 广东康尔医疗科技有限公司 | Sms无纺布及其生产线及其生产方法 |
CN113548935A (zh) * | 2021-06-22 | 2021-10-26 | 南京理工大学 | 一种核壳结构的硼-硝酸钾及其制备方法 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03292960A (ja) * | 1990-04-11 | 1991-12-24 | Shimizu Corp | 共有空間の消臭方法及び装置 |
JPH04128234A (ja) * | 1990-09-19 | 1992-04-28 | Suntory Ltd | 入眠促進剤 |
JPH05280784A (ja) * | 1991-04-18 | 1993-10-26 | Norm Pacific Autom Corp | 室内雰囲気制御装置 |
JPH0796025A (ja) * | 1993-08-04 | 1995-04-11 | Astec Internatl:Kk | 空気清浄化装置及び空気清浄化方法 |
JP2000281585A (ja) * | 1999-03-30 | 2000-10-10 | Kunikazu Suzuki | 室内空間加湿用雰囲気療法剤 |
JP2003513719A (ja) * | 1999-11-05 | 2003-04-15 | パリ ゲゼルシャフトミット ベシュレンクテル ハフツング スペツィアリステン フィア エフェクティブインハレーション | 吸入用噴霧器 |
WO2003047580A1 (en) * | 2001-11-30 | 2003-06-12 | The Boots Company Plc | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
JP2003183174A (ja) * | 2001-12-19 | 2003-07-03 | Fancl Corp | 不眠症用組成物 |
JP2003522147A (ja) * | 2000-02-11 | 2003-07-22 | アクゾ・ノベル・エヌ・ベー | 睡眠障害の治療のためのミルタザピンの使用 |
JP2003252755A (ja) * | 2002-03-04 | 2003-09-10 | Pharmafoods Kenkyusho:Kk | 癒し効果組成物 |
JP2004269361A (ja) * | 2003-03-04 | 2004-09-30 | Pharmafoods Kenkyusho:Kk | 成長ホルモン分泌促進組成物 |
JP2005139135A (ja) * | 2003-11-07 | 2005-06-02 | Nisshin Pharma Inc | 更年期障害の予防改善剤 |
JP2005232045A (ja) * | 2004-02-18 | 2005-09-02 | Taiyo Kagaku Co Ltd | 抗ストレス及びリラックス用組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5193354A (en) * | 1992-01-31 | 1993-03-16 | Itamar Kleinberger | Humidification system with droplet discrimination |
US5439873A (en) * | 1994-02-23 | 1995-08-08 | Plant Growth Development Corporation | Method for stimulating plant growth using GABA |
US20020073991A1 (en) * | 1998-01-22 | 2002-06-20 | Igor Gonda | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
NZ509231A (en) * | 1998-07-09 | 2003-08-29 | Warner Lambert Co | Use of GABA analogs to treat insomnia |
US6497658B2 (en) * | 1999-12-19 | 2002-12-24 | Michael F. Roizen | Alarm upon detection of impending sleep state |
ATE419844T1 (de) * | 2000-02-10 | 2009-01-15 | Kao Corp | Verwendung von sesquiterpenalkohol zur regulierung des autonomen nervensystems |
CZ299755B6 (cs) * | 2001-05-25 | 2008-11-12 | Warner-Lambert Company Llc | Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití |
-
2005
- 2005-10-14 EP EP05793078A patent/EP1806133A1/en not_active Withdrawn
- 2005-10-14 WO PCT/JP2005/018957 patent/WO2006041158A1/ja active Application Filing
- 2005-10-14 AU AU2005292853A patent/AU2005292853C1/en not_active Ceased
- 2005-10-14 US US11/665,223 patent/US20080112893A1/en not_active Abandoned
- 2005-10-14 CN CNA2005800347228A patent/CN101039664A/zh active Pending
- 2005-10-14 KR KR1020077010703A patent/KR100870381B1/ko not_active IP Right Cessation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03292960A (ja) * | 1990-04-11 | 1991-12-24 | Shimizu Corp | 共有空間の消臭方法及び装置 |
JPH04128234A (ja) * | 1990-09-19 | 1992-04-28 | Suntory Ltd | 入眠促進剤 |
JPH05280784A (ja) * | 1991-04-18 | 1993-10-26 | Norm Pacific Autom Corp | 室内雰囲気制御装置 |
JPH0796025A (ja) * | 1993-08-04 | 1995-04-11 | Astec Internatl:Kk | 空気清浄化装置及び空気清浄化方法 |
JP2000281585A (ja) * | 1999-03-30 | 2000-10-10 | Kunikazu Suzuki | 室内空間加湿用雰囲気療法剤 |
JP2003513719A (ja) * | 1999-11-05 | 2003-04-15 | パリ ゲゼルシャフトミット ベシュレンクテル ハフツング スペツィアリステン フィア エフェクティブインハレーション | 吸入用噴霧器 |
JP2003522147A (ja) * | 2000-02-11 | 2003-07-22 | アクゾ・ノベル・エヌ・ベー | 睡眠障害の治療のためのミルタザピンの使用 |
WO2003047580A1 (en) * | 2001-11-30 | 2003-06-12 | The Boots Company Plc | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
JP2003183174A (ja) * | 2001-12-19 | 2003-07-03 | Fancl Corp | 不眠症用組成物 |
JP2003252755A (ja) * | 2002-03-04 | 2003-09-10 | Pharmafoods Kenkyusho:Kk | 癒し効果組成物 |
JP2004269361A (ja) * | 2003-03-04 | 2004-09-30 | Pharmafoods Kenkyusho:Kk | 成長ホルモン分泌促進組成物 |
JP2005139135A (ja) * | 2003-11-07 | 2005-06-02 | Nisshin Pharma Inc | 更年期障害の予防改善剤 |
JP2005232045A (ja) * | 2004-02-18 | 2005-09-02 | Taiyo Kagaku Co Ltd | 抗ストレス及びリラックス用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN101039664A (zh) | 2007-09-19 |
US20080112893A1 (en) | 2008-05-15 |
KR100870381B1 (ko) | 2008-11-25 |
AU2005292853B2 (en) | 2009-08-20 |
AU2005292853A1 (en) | 2006-04-20 |
AU2005292853C1 (en) | 2010-08-05 |
KR20070063039A (ko) | 2007-06-18 |
EP1806133A1 (en) | 2007-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090126722A1 (en) | Liquid ejection device and ejection method | |
RU2367466C2 (ru) | Эжекционная жидкость, способ эжекции, способ формирования капель жидкости, картридж для эжекции жидкости и эжекторное устройство | |
JP4147234B2 (ja) | 吐出用液体、吐出方法、カートリッジ及び吐出装置 | |
JP5863641B2 (ja) | 濃縮肥満細胞安定化用薬学的調合物 | |
RU2364412C2 (ru) | Эжектируемая жидкость, способ эжектирования, способ получения мелких капель из жидкости, картридж и эжекционное устройство | |
WO2006041158A1 (ja) | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 | |
JP2002532163A (ja) | 経鼻式吸入器 | |
CN101053685A (zh) | 便携式雾化给药装置 | |
CN103619323B (zh) | 作为气溶胶团的伊洛前列素的给药 | |
JP2007254421A (ja) | 吐出用液体、吐出方法、吐出用カートリッジ、吐出装置及び吐出用液体の液滴化方法 | |
JP2007136451A (ja) | 液体吐出装置及び吐出方法 | |
WO2007119684A1 (ja) | 噴霧剤 | |
WO2006070739A1 (ja) | 噴霧装置 | |
JP2006137748A (ja) | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 | |
JP2007275745A (ja) | 静電噴霧装置 | |
JP2006231133A (ja) | 静電噴霧装置 | |
JP2007056032A (ja) | 噴霧装置 | |
JP6228220B2 (ja) | エアロゾル化イロプロストの投与 | |
WO2008094693A2 (en) | Compositions for aerosolization of highly conductive solutions | |
JP3861901B2 (ja) | 静電噴霧装置 | |
JP3861921B2 (ja) | 静電噴霧装置 | |
WO2003082242A2 (en) | Highly aqueous liquid carrier formulations | |
JP2008055264A (ja) | 有用物噴霧システム | |
AU2008203785A1 (en) | Compositions for aerosolization and inhalation | |
RU2001120381A (ru) | Назальный ингалятор |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580034722.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665223 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005793078 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005292853 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077010703 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005292853 Country of ref document: AU Date of ref document: 20051014 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005793078 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11665223 Country of ref document: US |